TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy Ahead of Schedule
核心洞察
TaiMed Biologics (搜索) completed Phase 2b enrollment for TMB-365/380 (搜索), a dual broadly neutralizing antibody combination for HIV (搜索) maintenance therapy, ahead of schedule with interim analysis expected by year-end 2026.
The investigational therapy aims to provide viral suppression without requiring baseline susceptibility screening, potentially differentiating it from existing long-acting HIV (搜索) treatments like lenacapavir and cabotegravir-rilpivirine (搜索).
The company estimates peak annual global sales of $3-4 billion for TMB-365/380 (搜索) and is actively seeking licensing and co-development partnerships for global commercialization.
TaiMed Biologics (搜索) has completed enrollment in its Phase 2b clinical study of TMB-365/380 (搜索), a novel dual broadly neutralizing antibody (bNAb) combination for HIV (搜索) maintenance therapy, reaching Last Patient In ahead of the planned schedule. The company announced that an interim analysis is anticipated by year-end 2026, which will inform plans for the next stage of development and potential regulatory submissions.
Differentiated Approach to Long-Acting HIV Therapy
The TMB-365/380 (搜索) program represents a potentially significant advancement in the long-acting HIV (搜索) therapy landscape. Unlike existing approved long-acting HIV regimens that require patient selection through resistance testing or susceptibility confirmation, TaiMed's dual-bNAb cocktail is designed to achieve viral suppression without requiring baseline susceptibility screening.
"We believe TMB-365/380 (搜索) has the potential to be the first long-acting bNAb combination to demonstrate high rates of viral suppression without the need for susceptibility screening, a distinction that could improve clinical access and patient convenience," said Dr. Jimmy Chang, Chief Executive Officer of TaiMed Biologics (搜索).
The therapy is administered every two months (Q2M) as a first-line HIV (搜索) maintenance therapy for people living with HIV. This dosing frequency positions it strategically between ViiV (搜索)'s cabotegravir plus rilpivirine, which requires monthly injections initially then every two months, and Gilead's lenacapavir, which achieved every-six-month subcutaneous dosing in the PURPOSE trials.
Clinical Progress and Early Indicators
Preliminary observations from ongoing follow-up show that viral suppression and relevant biomarkers following the first two doses are fully consistent with the company's expectations. The accelerated enrollment reflects strong engagement from clinical sites and interest in Q2M long-acting treatment approaches, according to the company.
Subject to continued positive outcomes, TaiMed plans to submit a Breakthrough Therapy Designation (BTD) application to the U.S. Food and Drug Administration (FDA). The interim readout arriving before December 2026 represents a critical inflection point that will determine whether the dual-bNAb combination advances toward a pivotal program.
Commercial Potential and Strategic Partnerships
TaiMed estimates peak annual global sales of TMB-365/380 (搜索) at approximately $3-4 billion. The company believes the therapy's potential to offer a long-acting, infrequent-dosing treatment option without susceptibility screening requirements may support broad clinical use and differentiation within the evolving HIV (搜索) treatment landscape.
The biotechnology company is actively exploring potential strategic partnerships, including licensing and co-development opportunities, to support the global development and commercialization of TMB-365/380 (搜索). The interim data package expected at year-end will serve as a deal-enabling document for potential partners in the HIV (搜索) franchise space.
Company Background
Founded in 2007, TaiMed Biologics (搜索) is a commercial-stage biotechnology company that successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV (搜索). The company also offers comprehensive contract development and manufacturing (CDMO) services and is publicly traded on the OTC Market, currently part of the MSCI Small Cap Index.